Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann-Charlott Steffen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
International Journal of Radiation Oncology, Biology, Physics|December 26, 2006
Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak basesAsa Liljegren Sundberg, Ann-Charlott Steffen
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|May 3, 2006
Effects of HER2-binding affibody molecules on intracellular signaling pathwaysLina Ekerljung, Ann-Charlott Steffen, Jorgen Carlsson, et al.
Nuclear Medicine and Biology|May 15, 2003
Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextranAsa Liljegren Sundberg, Erik Blomquist, Jörgen Carlsson, et al.
Nuclear Medicine and Biology|November 28, 2006
In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancerYlva Almqvist, Ann-Charlott Steffen, Vladimir Tolmachev, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 7, 2007
Biodistribution of 211At-labeled humanized monoclonal antibody A33Ylva Almqvist, Ann-Charlott Steffen, Hans Lundqvist, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 15, 2008
Differences in radiosensitivity between three HER2 overexpressing cell linesAnn-Charlott Steffen, Lovisa Göstring, Vladimir Tolmachev, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 15, 2005
Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factorErika Nordberg, Ann-Charlott Steffen, Mikael Persson, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 2, 2005
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnosticsAnn-Charlott Steffen, Maria Wikman, Vladimir Tolmachev, et al.
Oncology Reports|March 29, 2007
Biodistribution of 211At labeled HER-2 binding affibody molecules in miceAnn-Charlott Steffen, Ylva Almqvist, Ming-Kuan Chyan, et al.
Bioanalysis|February 19, 2013
Capillary microsampling and analysis of 4-µl blood, plasma and serum samples to determine human α-synuclein elimination rate in miceOve Jonsson, Ann-Charlott Steffen, Valentina Screpanti Sundquist, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
International Journal of Radiation Oncology, Biology, Physics|December 26, 2006
Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak basesAsa Liljegren Sundberg, Ann-Charlott Steffen
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|May 3, 2006
Effects of HER2-binding affibody molecules on intracellular signaling pathwaysLina Ekerljung, Ann-Charlott Steffen, Jorgen Carlsson, et al.
Nuclear Medicine and Biology|May 15, 2003
Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextranAsa Liljegren Sundberg, Erik Blomquist, Jörgen Carlsson, et al.
Nuclear Medicine and Biology|November 28, 2006
In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancerYlva Almqvist, Ann-Charlott Steffen, Vladimir Tolmachev, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 7, 2007
Biodistribution of 211At-labeled humanized monoclonal antibody A33Ylva Almqvist, Ann-Charlott Steffen, Hans Lundqvist, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 15, 2008
Differences in radiosensitivity between three HER2 overexpressing cell linesAnn-Charlott Steffen, Lovisa Göstring, Vladimir Tolmachev, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 15, 2005
Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factorErika Nordberg, Ann-Charlott Steffen, Mikael Persson, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 2, 2005
In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnosticsAnn-Charlott Steffen, Maria Wikman, Vladimir Tolmachev, et al.
Oncology Reports|March 29, 2007
Biodistribution of 211At labeled HER-2 binding affibody molecules in miceAnn-Charlott Steffen, Ylva Almqvist, Ming-Kuan Chyan, et al.
Bioanalysis|February 19, 2013
Capillary microsampling and analysis of 4-µl blood, plasma and serum samples to determine human α-synuclein elimination rate in miceOve Jonsson, Ann-Charlott Steffen, Valentina Screpanti Sundquist, et al.
Pageof 2